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the severity of AR after TAVI as compared to c-MRI. Furthermore, there is a
poor correlation between c-MRI and TTE or angiography. Further studies are
mandatory to confirm our results in a larger population. 
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Background: Previous studies suggested that a low flow defined as an
indexed stroke volume (SVi) < 35 ml/m2 may be an important determinant of
outcome in patients with severe aortic stenosis (AS). However, its quantifica-
tion using echocardiography may be subject to error measurement. The aim of
this study is to determine the impact of low SVi determined during cardiac
catheterization on long-term survivalamong patients with severe aortic ste-
nosis and preserved LV ejection fraction.
Methods and Results: Between 2000 and 2010, 768 patients with pre-
served LVEF (>50%) and severe AS (valve area ≤1cm²) without other val-
vular heart disease underwent cardiac catheterization. SVi was derived from
catheterization data.
Mean age was 74±8 years, 42% were female, 46% had coronary artery dis-
ease and mean LVEF was 72±10%. Overall, low SVi was found in 27%
(n=...) of AS patients.
As compared to patients with normal SVi, those with decreased SVi were sig-
nificantly older (p<0.0001) and had more frequently atrial fibrillation (p<0.0001)
in addition, they had lower LVEF (p=0.04),; aortic valve area (p<0.0001), mean
pressure gradient (p= 0.001), systemic arterial compliance (p<0.0001) and higher-
systemic vascular and pulmonary resistances (p<0.0001). 
Ten-year survival was significantly reduced in patients with lower SVi
as compared to those with normal SVi (41±5% vs. 63±3%; p=0.0007,
Figure). After adjustment for all other risk factors, SVi was independently
associated with long-term survival (hazard ratio =0.97, 95%CI: 0.95-0.99;
p=0.01). 
Conclusion: Low SVi measured invasively is frequent in patients with
severe AS and preserved LVEF and is a powerful and independent predictor
of survival. SVi should be systematically measured and used as an additional
parameter for risk stratification of patients with severe AS. 
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Objectives: To evaluate feasibility, safety and advantage of underexpan-
sion of Edwards SAPIEN XT prosthesis during transcatheter aortic valve
implantation (TAVI).
Methods: We retrospectively analyzed 157 transfemoral TAVI proce-
dures performed between October 2012 and December 2013 in the Univer-
sity Hospital of Rouen. Thirty-six (22.9%) patients had intentional
underexpansion of the EDWARDS SAPIEN XT prosthesis since more than
20% area oversizing was anticipated with Computed tomography (CT)
assessment of aortic annulus. Underexpansion of Edwards SAPIEN XT
prosthesis was performed by reducing the volume of fluid within the valve
deployment balloon. The Primary endpoint was aortic regurgitation (AR)
at the end of the procedure. 
Results: Mean age was 83.4±5.8 years and the mean logistic EuroSCORE
of 15.4±9.6%. The initial fluid volume used for valve deployment was
90.1±3.1% of the theorical total volume (TTV) without significant difference
among the 3 sizes of prostheses (90.2±4.1%, 89.5±2.6%, and 84.8±3.2% for
23, 26, and 29-mm valves, respectively). AR immediately after the first infla-
tion was grade ≤I in 20 (55.6%) pts, grade II in 9 (25%) pts, and grade III in
7 (19.4%) pts. Stent diameter measured immediately after first inflation repre-
sented 94.2±4.1% of the prosthesis theorical diameter. Post-dilatation was
deemed necessary in 14 cases (39.4%). At the end of the procedure, AR was
< grade I in 34 (94.4%) patients and grade II in the 2 remaining patients. After
post-dilatation, one patient presenting with fatal aortic annulus rupture. Other
procedures were safe without stroke, myocardial infarction, or prosthesis
migration. 
Conclusion: Our study suggest that underexpansion of Edwards SAPIEN-
XT prosthesis is feasible during transfemoral TAVI procedures when more
than 20% area oversizing is anticipated by CT. However, post-dilatation is
mandatory in about 40% of cases to reduce significant residual aortic regurgi-
tation but can be complicated by aortic annulus rupture 
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Aim: Transcatheter aortic valve implantation (TAVI) is an alternative to
surgical aortic valve replacement for high-risk patients. The relative event
rates following TAVI have not yet been well described and seem to differ
between genders. We sought to determine gender imbalances in TAVI patients
with regard to baseline presentation, management, and prognosis.
Methods and results: A total of 3,972 patients underwent TAVI and were
prospectively included in the FRANCE 2 registry.
Women (n=1967) presented with older age and lower rates of coronary
artery disease, chronic obstructive pulmonary disease, renal failure, and
arrhythmia, though higher prevalence of hypertension and congestive heart
failure (43.7% vs. 39.7%; p=0.010). EuroSCORE was similar between gen-
ders. Women presented with smaller aortic annulus and were implanted with
smaller bioprostheses.
At 1 month, mortality rates were similar between genders. Multivariate
analysis revealed the following independent predictors for 1-month all-cause
mortality: female gender; New York Heart Association (NYHA) Class III or
IV; transapical approach; moderate to severe postprocedural aortic regurgita-
tion. We observed a specific interaction between gender and EuroSCORE,
confirming EuroSCORE as less capable to discriminate women in order to
establish 1-month mortality. Women presented with lower 1-year mortality
rates than men (19.3% vs. 23.7%; p=0.021). Female gender was an indepen-
dent predictor of 1-year survival (HR: 0.71, 95% CI: [0.57-0.88]).
Conclusion: Men and women exhibited several differing baseline charac-
teristics, as well as procedural and clinical outcomes. Notably, Euroscore
proved inconvenient for 1-month survival prediction in women. Women also
presented with an 18.5% decrease in 1-year all-cause mortality compared to
men. 
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There is currently no consensus on the duration of monitoring required
after TAVI. Between october 2009 and november 2013, 371 consecutive
patients underwent transfemoral TAVI in our institution, all performed using
the Edwards SAPIEN-XT prosthesis and local anesthesia.
All the patients were monitored in intensive care unit for at least 24 hours after
TAVI. We excluded 12 Patients implanted with a Corevalve, 14 patients who died
before discharge, and 8 patients who were not discharge d straight home.
The remaining 337 patients were discharged at home, 121 (36%) within
3 days (early discharge group) and 216 (64%) more than 3 days after TAVI
(conventional discharge group).
The primary end point combined death and re-hospitalization at 30 days.
All adverse events were adjudicated according to the Valve Academic
Research Consortium-2.
The incidence of early discharge rose from 0% in 2009 to 53.2% of cases
in 2013. Before (plutôt prior to?) TAVI, patients in the early discharge group
were less symptomatic (NYHA >III: 64.5% vs. 75.5%, p=0.01) and had less
renal failure (creatinine: 102.1±41.0 vs. 113.3±58.9μmol/l, p=0.04), less atrial
fibrillation (33.1% vs. 46.3%, p=0.02), and less previous balloon aortic valvu-
loplasty (11.6% vs. 23.1%, p=0.01) than those in the conventional discharge
group. In contrast, patients in the early discharge group were more likely to
have a pacemaker before TAVI (16.5% vs. 8.3%, p=0.02).
After multivariable analysis, pacemaker before TAVI (OR 0.44; 95% CI
0.19-0.99; p=0.05), previous balloon aortic valvuloplasty (OR 2.26; 95% CI
1.10-4.64; p=0.03), transfusions (OR 9.6; 95% CI 2.36-38.94; p=0.002), and
delta creatinin (OR 0.99; 95% CI 0.98-0.99; p=0.02) were independent predic-
tive factors of early discharge. The primary end-point occurred in 7 (5.8%)
patients in the early discharge group and in 16 (7.1%) patients in the conven-
tional discharge group without significant difference (p=0.60). No patients
died in the early discharge group at 30-day follow-up.
The results of our study suggest that early discharge is feasible and safe
after TAVI using the Edwards-SAPIEN XT prosthesis in selected patients 
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Background: Aortic valve stenosis (AVS) can be complicated by bleeding
associated with acquired type 2A von Willebrand syndrome. The association
of AVS and gastrointestinal bleeding from angiodysplasia is defined as
Heyde's syndrome. We sought to evaluate the impact of TAVI on primary
hemostasis disorders and to assess its effectiveness to treat Heyde's syndrome. 
Methods: We prospectively enrolled 49 consecutive patients with severe
AVS referred to our institution for TAVI. Biological primary hemostasis
parameters were assessed at baseline and one week after the procedure. 
Results: At baseline, a significant link between vWF abnormalities and the
severity of AVS was evidenced: mean aortic transvalvular gradient was nega-
tively correlated with the levels of vWF antigen (vWF: Ag) (r=–0.29, p<0.05),
vWF ristocetin cofactor activity (vWF:RCo) (r=–0.402, p=0.006) and vWF col-
lagen-binding activity (vWF:CB) (r=–0.441, p=0.005). One week after the pro-
cedure, a significant increase of vWF:Ag, vWF:RCo, and vWF:CB was
evidenced in the whole cohort (respectively 3.32 vs 2.29 IU/mL, p<0.001; 2.98
vs 1.86 IU/mL, p<0.001; 3.16 vs 2.16 IU/mL, p<0.001). Patients with pre-TAVI
vWF abnormalities consistent with a type 2A vWF syndrome (ratio vWF:CB/
vWF:Ag <0.7) preferentially improved their vWF function with respect to
patients with a normal ratio (relative increase of vWF:CB of 63.8% vs 3.5%). 
Conclusion: Primary hemostasis parameters involving vWF are improved
after TAVI, especially in patients with preexisting abnormalities consistent
with acquired type 2A von Willebrand syndrome. Moreover, our observations,
although limited to a small single-center study, suggest that Heyde's syndrome
can be cured by TAVI.
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Introduction: systolic pulmonary artery pressure (sPAP) is a well known
predictor of outcome in patients with valvular heart disease. In spite of this
fact, limited data are available regarding the assessment of RV function in
patients with aortic stenosis (AS). 
Aim: of this study is therefore to evaluate the prevalence and the determi-
nants of RV dysfunction in severe AS patients
Methods: 201 patients (mean age:79.7±8.7, male sex 55.5%) with severe
AS underwent 2D echocardiography and speckle tracking echocardiography
(STE) for the evaluation of left ventricular and RV function, aortic valve gra-
dients and sPAP. A tricuspid annular plane systolic excursion (TAPSE)
≤17mm was used to define reduced RV ventricular function. 
Results: RV function was impaired in 48 patients (24%). Patients with
reduced TAPSE had an impaired LV ejection fraction (LVEF) (49.2±15.4 vs
57.9±10.9%, p<0.0001), significantly altered STE parameters (GLS: –10.3
±3.9 vs –13.2±3.5%, GCS: –7.0±3. vs –10.4±4.9%, GRS: 18.7±11.6 vs
28.4±15.6, all p<0.001) and a higher sPAP (48.4±15.8 vs 40.9±12.7 mmHg,
p=0.002) with respecto to patients with a normal RV function. Correlates of a
reduced TAPSE were: LVEF (β=0.35, p<0.0001), LV global longitudinal, cir-
cumferential and radial strain (β=–0.40, β=–0.40, β=0.37 respectively, all
p<0.0001), LV indexed stroke volume (β=0.44, s<0.0001), lnNT-proBNP
(β=–0.51, p<0.0001) and sPAP (β=–0.27, p<0.0001). At Kaplan-Meier sur-
vival curve, a TAPSE ≤17mm was associated with a reduced survival in
patients with AS (Log Rank test, p=0.034).
Conclusions: In patients with severe AS, RV function impairment is fre-
quent and is associated with a poor prognosis. The correlations of TAPSE
highlight the RV-LV interdependence in AS patients. Further studies will
clarify the real and independent prognostic value of RV function in severe AS
patients and test for the RV reverse remodelling after treatment of the AS. 
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Introduction: in patients with aortic stenosis (AS), the occurrence of
adverse outcomes does not always correspond to the classical markers of hae-
modynamic severity. Moreover, the evaluation of outcomes in these patients
is often biased by considering surgery as a censor event at follow-up analysis.
Aim of the present study is therefore to evaluate the determinants of prognosis
in patients with severe AS, independently from the treatment modality (aortic
valve replacement/medical therapy).
Methods: 220 patients (mean age: 79.8±8.6 years, male sex: 119, 54%)
with severe AS (aortic valve surface <1cm2 or <0.6cm2/m2) underwent
standard echocardiography to characterize aortic valve gradients and biventri-
cular function. Hospitalization for cardiac cause, heart failure, overall death,
but not intervention on the aortic valve were considered as major adverse car-
diac events (MACEs). 
Results: after a mean follow-up period of 7.8 months, the predefined MACEs
occurred in 57 patients (26%). At Cox regression analysis, LVESV (HR 1.20,
p=0.0025), age (HR 0.79, p=0.03), female sex (HR 1.43, P=0.05) and a Zva>3.2
mmHg/ml/m2 (HR 3.53, p<0.0001) were the strongest predictors of events.
Conclusions: In patients with severe AS, a ZVa >3.2 mmHg/ml/m2 is the
strongest predictor of prognosis, independently from the treatment modality.
The ventriculo-arterial interplay has thus a fundamental role in AS, defining
the natural history of the disease and suggesting that a careful reduction of LV
afterload could be very useful in the clinical management of these patients.
